Form 4: AbbVie Executive Exercises, Sells Shares

AbbVie's EVP, GC and Secretary, Perry C. Siatis, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 plan.

Summary

• Perry C. Siatis, Executive Vice President, General Counsel, and Secretary of AbbVie Inc. (ABBV), executed a series of transactions on February 25, 2026.
• Siatis exercised employee stock options to acquire a total of 22,381 shares of AbbVie Common Stock.
• The options were exercised at strike prices of $149.62 for 7,314 shares, $175.28 for 7,775 shares, and $192.86 for 7,292 shares.
• Immediately following the option exercises, Siatis sold all 22,381 acquired shares at a price of $230 per share.
• These transactions were conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following these transactions, Siatis's direct beneficial ownership of AbbVie Common Stock is 38,137 shares.
• Siatis retains 7,774 unexercised options from one grant (exercisable at $175.28) and 14,583 unexercised options from another grant (exercisable at $192.86).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It represents a routine executive compensation transaction under a pre-arranged plan, with no direct positive or negative implications for the company's operational performance or future prospects.

Positives

• The executive realized gains from exercising options, indicating personal financial benefit from their compensation package.
• The transactions were conducted under a Rule 10b5-1 plan, suggesting pre-planned activity and not a reaction to immediate, non-public company news.

Negatives

• The sale of all shares acquired through option exercise, rather than holding them, could be interpreted as the executive diversifying their portfolio or taking profits, which is a common practice.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the pharmaceutical industry as a mechanism for executives to manage their equity compensation and diversify personal holdings in a compliant manner. These transactions typically reflect individual financial planning rather than a direct signal about the company's immediate operational performance or strategic direction.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned executive transaction and does not reflect a change in company fundamentals.
• Employees: No direct impact on the broader employee base.

Next Steps

• Remaining tranches of options from Option 2 (7,774 shares) become exercisable on February 15, 2027.
• Remaining tranches of options from Option 3 (7,292 shares on February 13, 2027, and 7,291 shares on February 13, 2028) become exercisable.

Key Dates

Recommendation

The filing details a routine, pre-planned executive stock option exercise and sale under a 10b5-1 plan. Such transactions are common for executive compensation and typically do not signal a change in the company's fundamental outlook or warrant a change in investment strategy. Therefore, a 'hold' recommendation is appropriate as this event provides no new material information to alter an existing investment thesis.

Keywords

AbbVie, ABBV, Insider Trading, Form 4, Stock Options, Executive Compensation, Perry C. Siatis, 10b5-1 Plan, Share Sale, Pharmaceuticals